Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Touzeau

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Bone Marrow Transplantation|April 5, 2016
Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myelomaS Wuillème, A Lok, N Robillard, et al.
Leukemia & Lymphoma|February 28, 2007
Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implicationsC Touzeau, C Pellat-Deceunynck, T Gastinne, et al.
Leukemia|July 18, 2013
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myelomaC Touzeau, C Dousset, S Le Gouill, et al.
Bone Marrow Transplantation|April 4, 2017
Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrierA Garnier, T Guillaume, P Peterlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center studyA Lassalle, P Thomaré, C Fronteau, et al.
Journal of Hematology & Oncology|January 18, 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert PanelJ Caers, B Paiva, E Zamagni, et al.
Annals of Hematology|April 5, 2017
Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomasB Tessoulin, P Thomare, E Delande, et al.
Studies in Health Technology and Informatics|October 6, 2004
Sagittal profile of the spine prominent part of the pelvisG Duval-Beaupere, C Marty, F Barthel, et al.
Annals of Hematology|June 15, 2016
Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experienceJ Bourcier, T Gastinne, C Leux, et al.
Leukemia|April 6, 2013
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaX Leleu, G Fouquet, B Hebraud, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Bone Marrow Transplantation|April 5, 2016
Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myelomaS Wuillème, A Lok, N Robillard, et al.
Leukemia & Lymphoma|February 28, 2007
Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implicationsC Touzeau, C Pellat-Deceunynck, T Gastinne, et al.
Leukemia|July 18, 2013
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myelomaC Touzeau, C Dousset, S Le Gouill, et al.
Bone Marrow Transplantation|April 4, 2017
Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrierA Garnier, T Guillaume, P Peterlin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center studyA Lassalle, P Thomaré, C Fronteau, et al.
Journal of Hematology & Oncology|January 18, 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert PanelJ Caers, B Paiva, E Zamagni, et al.
Annals of Hematology|April 5, 2017
Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomasB Tessoulin, P Thomare, E Delande, et al.
Studies in Health Technology and Informatics|October 6, 2004
Sagittal profile of the spine prominent part of the pelvisG Duval-Beaupere, C Marty, F Barthel, et al.
Annals of Hematology|June 15, 2016
Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experienceJ Bourcier, T Gastinne, C Leux, et al.
Leukemia|April 6, 2013
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaX Leleu, G Fouquet, B Hebraud, et al.
Pageof 3